

Synthesis and antimicrobial evaluation of some 1,3-thiazole, 1,3,4-thiadiazole, 1,2,4-triazole, and 1,2,4-triazolo[3,4-*b*][1,3,4]-thiadiazine derivatives including a 5-(benzofuran-2-yl)-1-phenylpyrazole moiety

Bakr F. Abdel-Wahab · Hatem A. Abdel-Aziz ·
Essam M. Ahmed

Received: 7 July 2008 / Accepted: 29 October 2008 / Published online: 2 December 2008
© Springer-Verlag 2008

Abstract Potassium hydrazinecarbodithioate were prepared by treatment of acid hydrazides with carbon disulfide in the presence of potassium hydroxide. Reaction of this potassium salt with hydrazine hydrate, phenacyl bromide, or hydrazoneyl chlorides afforded 1,2,4-triazole, 1,3-thiazole, and 1,3,4-thiadiazoles. Reaction of 1,2,4-triazole with phenacyl bromide or hydrazoneyl chlorides afforded the corresponding 1,2,4-triazolo[3,4-*b*][1, 3, 4]-thiadiazines. All these new compounds were screened for antibacterial and antifungal activity. Some had promising activity.

Keywords 2-Acetylbenzofuran · Hydrazoneyl chlorides · Antimicrobial activity

Introduction

Benzofurans have attracted much attention over the last few years because of their profound physiological and chemotherapeutic properties and their widespread occurrence in nature [1, 2]. The antimicrobial activity of benzofuran derivatives seems to be more dependent on substitution on the heterocyclic furan ring than on substitution on the benzene moiety [3, 4]. Use of benzofurans as fungal *N*-myristoyltransferase (Nmt) inhibitors against human pathogenic *Candida albicans* has led to a novel group of fungicides [5, 6]. There are a few other

bimolecular targets which are sensitive to molecules containing benzofurans. Benzofuran-containing molecules also have in-vitro antibacterial activity. Examples include bacterial enzymes involved in the methionine cycle, for example methionine aminopeptidase [7] and deformylase [8], enzymes involved in peptidoglycan synthesis, for example UDP-*N*-acetylmuramyl-L-alanine ligase [9], and chorismate synthase, an enzyme in the shikimate pathway, essential for bacterial viability [10]. Compounds containing a pyrazole nucleus are known to have analgesic, anti-inflammatory, antipyretic, antiarrhythmic, tranquillizing, muscle relaxant, psychoanaleptic, anticonvulsant, hypotensive, monoamine oxidase inhibitor, antidiabetic, and antibacterial activity [11–18]. These facts coupled with our desire to develop efficacious antimicrobial agents, and in continuation of our work in heterocycles of biological interest [19–25], prompted us to devise an efficient and convenient method of synthesis of hitherto unknown and novel 1,3-thiazole, 1,3,4-thiadiazole, 1,2,4-triazole, and 1,2,4-triazolo[3,4-*b*][1,3,4]-thiadiazine derivatives with a 5-(benzofuran-2-yl)-1-phenylpyrazole nucleus. Results from assessment of the antimicrobial activity of these newly synthesized compounds are reported in this study.

Results and discussion

Chemistry

Recently, we prepared the acid hydrazide **4** [25] by reaction of 2-acetylbenzofuran (**1**) with diethyl oxalate in sodium methoxide to afford ethyl 4-(benzofuran-2-yl)-2,4-dioxobutanoate (**2**) which, on reaction with phenylhydrazine heated under reflux in glacial acetic acid, furnished the pyrazole derivative **3**. Reaction of this ester with

B. F. Abdel-Wahab (✉) · H. A. Abdel-Aziz
Department of Applied Organic Chemistry,
National Research Center, Dokki, Giza, Egypt
e-mail: Bakrfatehy@yahoo.com


E. M. Ahmed
Department of Natural and Microbial Products Chemistry,
National Research Center, Dokki, Giza, Egypt

hydrazine hydrate in absolute ethanol afforded the target hydrazide **4** [25] (Scheme 1).


Generally, acid hydrazides can be regarded as useful intermediates leading to the formation of several heterocycles, for example 1,2,4-triazoles and 1,2,4-triazolo[3,4-*b*][1,3,4]-thiadiazines [26, 27]. Treatment of acid hydrazide **4** with carbon disulfide in ethanol, in the presence of potassium hydroxide, resulted in the formation of the potassium salt of hydrazinecarbodithioate **5**. Treatment of the salt **5** with hydrazine hydrate in aqueous ethanol afforded the corresponding 4-amino-1,2,4-triazole-5-thione **6**. In contrast, treatment of **5** with phenacyl bromide in ethanol gave the 1,3-thiazole derivative **7**, whereas its reaction with hydrazonoyl chlorides **8a–8d**, namely 1-(2-phenylhydrazono)-1-chloropropan-2-one (**8a**), 1-(2-(4-bromophenyl)hydrazono)-1-chloropropan-2-one (**8b**), 1-(2-(4-chlorophenyl)hydrazono)-1-chloropropan-2-one (**8c**), or 1-(2-(4-fluorophenyl)hydrazono)-1-chloropropan-2-one (**8d**), under the same conditions, produced 1,3,4-thiadiazole derivatives **9a–9d** (Scheme 2). The structures of compounds **6**, **7**, and **9a–9d** was in agreement with spectral and analytical data. For example, the ^1H NMR spectrum of compound **7** contained a new singlet, not present in the spectrum of the starting material, at $\delta = 8.08$ ppm, attributed to *CH* of the 2-thioxothiazole ring, and the mass spectra of **6**, **7**, and **9a** contained molecular ion peaks at $m/z = 374$, 494, and 520, respectively, which was in agreement with their calculated masses.

Furthermore, the Schiff base **10** was produced by reaction of 4-amino-1,2,4-triazole-5-thione derivative **6** with 2-chloro-4-nitrobenzaldehyde heated under reflux in ethanol containing a few drops of glacial acetic acid as a catalyst. The reaction of **6** with phenacyl bromide or hydrazonoyl chlorides **8** in ethanol containing a catalytic amount of triethylamine furnished 1,2,4-triazolo[3,4-*b*][1,3,4]-thiadiazine derivatives **11** and **12a–12c** (Scheme 3).


The structures of compounds **10**, **11**, and **12a–12c** were established on the basis of both microanalytical and spectral data. For example, the ^1H NMR spectrum of compound



Scheme 1



Scheme 2



Scheme 3

10 contained a new singlet, not present in the spectrum of the starting material, at $\delta = 9.01$ ppm attributed to $-\text{N}=\text{CH}-$, whereas the ^1H NMR spectrum of compound **11** contained a singlet signal at $\delta = 4.35$ ppm corresponding to the two protons of $-\text{S}-\text{CH}_2$ in the thiadiazine ring. The mass spectrum of **12a** contained the molecular ion peak at $m/z = 516$, this was in exact agreement with the calculated mass.

Biology

The new compounds were tested for their antimicrobial activity, at a concentration of $100 \mu\text{g}/\text{cm}^3$, against five strains of microorganism, namely *Aspergillus niger*, *E. coli*, *Bacillus subtilis*, *Pseudomonas aeruginosa*, and *Candida*

Table 1 Antimicrobial activities of the newly synthesized compounds

Compound	Inhibition zone (mm)				
	<i>A. niger</i>	<i>E. coli</i>	<i>B. subtilis</i>	<i>P. aeruginosa</i>	<i>C. albicans</i>
5	20	12	20	20	30
6	20	20	15	15	30
7	–	12	20	20	25
9a	–	–	–	–	–
9b	–	–	–	–	–
9c	–	–	–	–	–
9d	15	15	–	–	30
10	20	20	–	20	40
11	–	20	–	–	20
12a	–	–	–	–	–
12b	–	–	–	–	20
12c	–	15	–	–	30

– indicates the compound has no activity

albicans. From the results in Table 1, we can conclude that compounds **6**, **10**, and **11** have equal activity against *E. coli* compared with the control, but **5**, **6**, **9d**, **10**, and **12c** resulted in the highest inhibition zones in plates seeded with *C. albicans*. The activity of the other compounds was low compared with that of flucanazol or amoxicillin. The growth inhibition zones are shown in Table 1.

We recently reported that some 3-substituted 5-(benzofuran-2-yl)pyrazole and 3-(benzofuran-2-yl)-4,5-dihydro-5-aryl-1-[4-(aryl)-1,3-thiazol-2-yl]-1H-pyrazole derivatives had significant antimicrobial activity against a variety of microorganisms [24, 25]. From structure–activity relationships it can be concluded that benzofuran, pyrazole, and thiazole moieties are essential for the antimicrobial activity. Also, increasing the number of nitrogen atoms sharply increases the antimicrobial activity.

Experimental

Chemistry

All melting points were taken on an Electrothermal IA 9000 series digital melting-point apparatus. Elemental analytical data were obtained by the microanalytical unit, Cairo University, Giza, Egypt, and results agreed favorably with calculated values. The IR spectra (KBr) were recorded by use of a Shimadzu CVT-04 spectrophotometer. The ¹H NMR spectra were recorded at 270 MHz on a Varian EM-360 spectrometer using TMS as internal standard. Mass spectra were recorded by use of a Varian MAT CH-5 spectrometer (70 eV). All reactions were monitored by TLC (aluminium foil-backed, 0.25 mm silica gel 60 F₂₅₄; Merck).

Potassium 2-(5-(benzofuran-2-yl)-1-phenyl-1H-pyrazole-3-carbonyl)hydrazinecarbodithioate (**5**)

To a solution of 3.18 g hydrazide **4** (10 mmol) in 100 cm³ ethanol, a solution of 0.84 g potassium hydroxide (15 mmol) in 10 cm³ water and 1.5 g carbon disulfide (20 mmol) were added. The reaction mixture was heated under reflux for 3 h then the solvent was evaporated under reduced pressure until dryness. The residue was then treated with 30 cm³ dry benzene and the precipitate which formed was collected by filtration, washed with ether, and dried to afford the potassium salt **5** in 76% yield. IR (KBr): $\bar{\nu}$ = 3,368, 3,128 (2NH), 1,648 (C=O) cm⁻¹.

4-Amino-3-(5-(benzofuran-2-yl)-1-phenyl-1H-pyrazol-3-yl)-1H-1,2,4-triazole-5(4H)-thione (**6**, C₁₉H₁₄N₆OS)

To a solution of 4.32 g **5** (10 mmol) in 20 cm³ ethanol and 10 cm³ water, 1 g hydrazine hydrate (20 mmol) was added. The reaction mixture was heated under reflux for 3 h, left to cool, and then poured on to crushed ice. The resulting solution was acidified with dilute hydrochloric acid to pH 7 and the resulting solid was collected by filtration, washed with water, and crystallized from ethanol to give 1,2,4-triazole-5-thione derivative **6** in 73% yield with m.p. 264–265 °C. IR (KBr): $\bar{\nu}$ = 1,296 (C=S), 1,629 (C=N), 3,321, 3,108, 3,058 (NH₂ and NH) cm⁻¹; ¹H NMR (DMSO-d₆): δ = 6.70 (s, 1H, pyrazole-H), 7.23 (s, 1H, benzofuran-H), 7.24–7.64 (m, 9H, Ar-H), 9.64 (s, 2H, NH₂, D₂O exchangeable), 12.52 (s, 1H, NH, D₂O exchangeable) ppm; MS: *m/z* (%) = 374 (M⁺, 0.59), 77 (100).

5-(Benzofuran-2-yl)-1-phenyl-N-(4-phenyl-2-thioxothiazol-3(2H)-yl)-1H-pyrazole-3-carboxamide (**7**, C₂₇H₁₈N₄O₂S₂)

A mixture of 0.86 g **5** (2 mmol) and 0.4 g phenacyl bromide (2 mmol) in 20 cm³ ethanol was heated under reflux for 3 h. The solid formed was collected by filtration, washed with ethanol, dried, and recrystallized from EtOH–DMF to afford **7** in 81% yield with m.p. 194–195 °C; IR (KBr): $\bar{\nu}$ = 1,642 (C=N), 1,667 (C=O), 3,230 (NH) cm⁻¹; ¹H NMR (DMSO-d₆): δ = 6.66 (s, 1H, pyrazole-H), 7.25 (s, 1H, benzofuran-H), 7.28–7.72 (m, 14H, Ar-H), 8.08 (s, 1H, CH), 9.31 (s, 1H, NH, D₂O exchangeable) ppm; MS: *m/z* (%) = 494 (M⁺, 0.11), 478 (100).

N'-(5-Acetyl-3-aryl-1,3,4-thiadiazol-2(3H)-ylidene)-5-(benzofuran-2-yl)-1-phenyl-1H-pyrazole-3-carbohydrazides **9a–9d**

To a solution of 0.86 g **5** (2 mmol) in 20 cm³ ethanol, 2 mmol of the appropriate hydrazonyl chloride **8a–8d** was added. The reaction mixture was heated under reflux for 3 h. The solid formed was collected by filtration, washed with ethanol, dried, and recrystallized from EtOH–DMF to afford **9a–9d**.

N'-(5-Acetyl-3-phenyl-1,3,4-thiadiazol-2(3*H*)-ylidene)-5-(benzofuran-2-yl)-1-phenyl-1*H*-pyrazole-3-carbohydrazide (**9a**, C₂₈H₂₀N₆O₃S)

Yield 84%, m.p. 249–250 °C; IR (KBr): $\bar{\nu}$ = 1,611 (C=N), 1,658, 1,685 (2 C=O), 3,113 (NH) cm⁻¹; ¹H NMR (DMSO-d₆): δ = 2.58 (s, 3H, CH₃), 6.54 (s, 1H, pyrazole-H), 7.25 (s, 1H, benzofuran-H), 7.27–8.06 (m, 14H, Ar-H), 11.38 (s, 1H, NH, D₂O exchangeable) ppm; MS: *m/z* (%) = 520 (M⁺, 67.89), 287 (100).

N'-(5-Acetyl-3-(4-bromophenyl)-1,3,4-thiadiazol-2(3*H*)-ylidene)-5-(benzofuran-2-yl)-1-phenyl-1*H*-pyrazole-3-carbohydrazide (**9b**, C₂₈H₁₉BrN₆O₃S)

Yield 86%, m.p. 254–255 °C; IR (KBr): $\bar{\nu}$ = 1,608 (C=N), 1,665, 1,687 (2 C=O), 3,180 (NH) cm⁻¹; ¹H NMR (DMSO-d₆): δ = 2.57 (s, 3H, CH₃), 6.56 (s, 1H, pyrazole-H), 7.24 (s, 1H, benzofuran-H), 7.27–8.06 (m, 13H, Ar-H), 11.29 (s, 1H, NH, D₂O exchangeable) ppm; MS: *m/z* (%) = 99 (M⁺, 66.20), 287 (100).

N'-(5-Acetyl-3-(4-chlorophenyl)-1,3,4-thiadiazol-2(3*H*)-ylidene)-5-(benzofuran-2-yl)-1-phenyl-1*H*-pyrazole-3-carbohydrazide (**9c**, C₂₈H₁₉ClN₆O₃S)

Yield 83%, m.p. 238–239 °C; IR (KBr): $\bar{\nu}$ = 1614 (C=N), 1,648, 1,685 (2 C=O), 3,180 (NH) cm⁻¹; ¹H NMR (DMSO-d₆): δ = 2.53 (s, 3H, CH₃), 6.62 (s, 1H, pyrazole-H), 7.21 (s, 1H, benzofuran-H), 7.25–8.03 (m, 13H, Ar-H), 11.54 (s, 1H, NH, D₂O exchangeable) ppm; MS: *m/z* (%) = 555 (M⁺, 49.52), 287 (100).

N'-(5-Acetyl-3-(4-fluorophenyl)-1,3,4-thiadiazol-2(3*H*)-ylidene)-5-(benzofuran-2-yl)-1-phenyl-1*H*-pyrazole-3-carbohydrazide (**9d**, C₂₈H₁₉FN₆O₃S)

Yield 75%, m.p. 258–260 °C; IR (KBr): $\bar{\nu}$ = 1,618 (C=N), 1,652, 1,690 (2 C=O), 3,198 (NH) cm⁻¹; ¹H NMR (DMSO-d₆): δ = 2.49 (s, 3H, CH₃), 6.53 (s, 1H, pyrazole-H), 7.19 (s, 1H, benzofuran-H), 7.18–7.78 (m, 13H, Ar-H), 11.38 (s, 1H, NH, D₂O exchangeable) ppm; MS: *m/z* (%) = 538 (M⁺, 68.08), 287 (100).

3-(5-(Benzofuran-2-yl)-1-phenyl-1*H*-pyrazol-3-yl)-4-(2-chloro-4-nitrobenzylideneamino)-1*H*-1,2,4-triazole-5(4*H*)-thione (**10**, C₂₆H₁₆ClN₇O₃S)

A mixture of 0.37 g 2-chloro-4-nitrobenzaldehyde (2 mmol) and 0.75 g **6** (2 mmol) in 20 cm³ ethanol and 0.2 cm³ glacial acetic acid was heated under reflux for 4 h. The solid product was collected by filtration, washed with ethanol, and crystallized from EtOH–DMF to afford 78% **10**, m.p. > 300 °C. IR (KBr): $\bar{\nu}$ = 1616 (C=N), 3,100 (NH) cm⁻¹; ¹H NMR (DMSO-d₆): δ = 6.60 (s, 1H, pyrazole-H), 7.20 (s, 1H, benzofuran-H), 7.24–7.64 (m, 12H, Ar-H), 9.01 (s, 1H, CH), 12.43 (s, H, NH, D₂O exchangeable) ppm; MS: *m/z* (%) = 541 (M⁺, 58.02), 77 (100).

3-(5-(Benzofuran-2-yl)-1-phenyl-1*H*-pyrazol-3-yl)-6-phenyl-7*H*-[1,2,4]triazolo[3,4-*b*][1,3,4]thiadiazine (**11**, C₂₇H₁₈N₆OS)

A mixture of 0.75 g **6** (2 mmol) and 0.4 g phenacyl bromide (2 mmol) in 30 cm³ absolute ethanol containing 0.2 g triethylamine (2 mmol) was heated under reflux for 3 h. The precipitate formed was isolated by filtration, washed with ethanol, dried, and recrystallized from EtOH–DMF to give **11** in 78% yield, m.p. 178–80 °C. IR (KBr): $\bar{\nu}$ = 1,599 (C=N) cm⁻¹; ¹H NMR (DMSO-d₆): δ = 4.35 (s, 2H, CH₂), 6.61 (s, 1H, pyrazole-H), 7.03 (s, 1H, benzofuran-H), 7.22–7.57 (m, 14H, Ar-H) ppm; MS: *m/z* (%) = 474 (M⁺, 9.03), 77 (100).

3-(5-(Benzofuran-2-yl)-1-phenyl-1*H*-pyrazol-3-yl)-7-(2-arylhydrazono)-6-methyl-7*H*-1,2,4-triazolo[3,4-*b*]-1,3,4-thiadiazines **12a–12c**

A mixture of 0.75 g **6** (2 mmol) and 2 mmol of the appropriate hydrazonyl chloride in 30 cm³ absolute ethanol containing 0.2 g triethylamine (2 mmol) was heated under reflux for 3 h. The precipitated solid was collected by filtration, washed with ethanol, dried, and then crystallized from EtOH–DMF to afford **12a–12c**.

3-(5-(Benzofuran-2-yl)-1-phenyl-1*H*-pyrazol-3-yl)-6-methyl-7-(2-phenylhydrazono)-7*H*-1,2,4-triazolo[3,4-*b*]-1,3,4-thiadiazine (**12a**, C₂₈H₂₀N₈OS)

Yield 62%, m.p. 268–9 °C; IR (KBr): $\bar{\nu}$ = 1,608 (C=N) cm⁻¹; ¹H NMR (DMSO-d₆): δ = 2.57 (s, 3H, CH₃), 6.60 (s, 1H, pyrazole-H), 7.08 (s, 1H, benzofuran-H), 7.38–8.06 (m, 14H, Ar-H), 11.62 (s, 1H, NH, D₂O exchangeable) ppm; MS: *m/z* (%) = 516 (M⁺, 9.03), 77 (100).

3-(5-(Benzofuran-2-yl)-1-phenyl-1*H*-pyrazol-3-yl)-7-(2-(4-chlorophenyl)hydrazono)-6-methyl-7*H*-1,2,4-triazolo[3,4-*b*]-1,3,4-thiadiazine (**12b**, C₂₈H₁₉ClN₈OS)

Yield 69%, m.p. 240–241 °C; IR (KBr): $\bar{\nu}$ = 1,619 (C=N) cm⁻¹; ¹H NMR (DMSO-d₆): δ = 2.54 (s, 3H, CH₃), 6.59 (s, 1H, pyrazole-H), 7.19 (s, 1H, benzofuran-H), 7.38–8.03 (m, 13H, Ar-H), 11.70 (s, 1H, NH, D₂O exchangeable) ppm; MS: *m/z* (%) = 551 (M⁺, 11.03), 77 (100).

3-(5-(Benzofuran-2-yl)-1-phenyl-1*H*-pyrazol-3-yl)-7-(2-(2,4-dichlorophenyl)hydrazono)-6-methyl-7*H*-1,2,4-triazolo[3,4-*b*]-1,3,4-thiadiazine (**12c**, C₂₈H₁₈Cl₂N₈OS)

Yield 65%, m.p. > 300 °C; IR (KBr): $\bar{\nu}$ = 1,612 (C=N) cm⁻¹; ¹H NMR (DMSO-d₆): δ = 2.55 (s, 3H, CH₃), 6.61 (s, 1H, pyrazole-H), 7.14 (s, 1H, benzofuran-H), 7.31–7.99 (m, 12H, Ar-H), 11.56 (s, 1H, NH, D₂O exchangeable) ppm; MS: *m/z* (%) = 585 (M⁺, 8.09), 77 (100).

Biology

The antimicrobial activity was determined applying the cup-plate agar-diffusion method [28]. Results were obtained in

duplicate, and results with differences higher than 5% were discarded and the measurement repeated.

References

1. Donnelly DMX, Meegan MJ, Katritzky AR, Ch Rees W (1984) *Comprehensive heterocyclic chemistry*, vol 4. Pergamon Press, Oxford, p 657
2. Cagniant P, Cagniant D, Katritzky AR, Boulton AJ (1975) *Advances in heterocyclic chemistry*, vol 18. Academic Press, New York, p 343
3. Bastian G, Royer R, Cavier R (1983) *Eur J Med Chem* 18:365
4. Khan MW, Alam MJ, Rashid MA, Chowdhury R (2005) *Bioorg Med Chem* 13:4796
5. Masubuchi M, Kawasaki K, Ebiike H, Ikeda Y, Tsujii S, Sogabe S, Fujii T, Sakata K, Shiratori Y, Aoki Y, Ohtsuka T, Shimma N (2001) *Bioorg Med Chem Lett* 11:1833
6. Ebiike H, Masubuchi M, Liu P, Kawasaki K, Morikami K, Sogabe S, Hayase M, Fujii T, Sakata K, Shindoh H, Shiratori Y, Aoki Y, Ohtsuka T, Shimma N (2002) *Bioorg Med Chem Lett* 12:607
7. Kawasaki K, Masubuchi M, Morikami K, Sogabe S, Aoyama T, Ebiike H, Niizuma S, Hayase M, Fujii T, Sakata K, Shindoh H, Shiratori Y, Aoki Y, Ohtsuka T, Shimma N (2003) *Bioorg Med Chem Lett* 13:87
8. Palmer LM, Janson CA, Smith WW Jr (2005) *PCT Int Patent* 016237
9. Christensen SB IV, Cummings MD, Lee J, Xiang J-N (2004) *PCT Int Patent* 098584
10. Ehmman DE, Demeritt JE, Hull KG, Fisher SL (2004) *Biochim Biophys Acta* 167:1698
11. Batulin YM (1969) *Farmacol Toksicol* 31: 533 (CA: 70, 2236a)
12. Parmar SS, Pandey BR, Dwivedi C, Harbison RD (1974) *J Pharm Sci* 63:1152
13. Soni N, Pande K, Kalsi R, Gupta TK, Parmar SS, Barthwal JP (1987) *Res Commun Chem Path Pharm* 56:129
14. Palaska E, Erol D, Demirdamar R (1996) *Eur J Med Chem* 31:43
15. Bruno O, Ranise A, Bondavalli F, Schenone F, D'Amico M, Filipelli A, Filipelli W, Francesco R (1993) *Farmaco* 48:949
16. Bondavalli F, Bruno O, Ranise A, Schenone F, Addonizio P, De Novellis V, Loffreda A, Marmo E (1988) *Farmaco* 43:725
17. Bruno O, Ranise A, Bondavalli F, Schenone P (1993) *Farmaco* 48:967
18. Mazzone G, Puglisi G, Corsaro A, Panico A, Bonina F, Amico-Roxas M, Caruso A, Trombadore S (1986) *Eur J Med Chem* 21:277
19. Amer FA, Hammouda M, El-Ahl A-A S, Abdel-Wahab BF (2007) *J Chin Chem Soc* 54:1543
20. Amer FA, Hammouda M, El-Ahl A-A S, Abdel-Wahab BF (2007) *Chem Heterocycl Compd* 43:1559
21. Abdel-Wahab BF, Mohamed SF, Amr AE, Abdalla MM (2008) *Monatsh Chem* 139:1083
22. Amr AE, Sabry NM, Abdalla MM, Abdel-Wahab BF (2008) *Eur J Med Chem* (in press)
23. Abdalla MM, Abdel-Wahab BF, Amr AE (2008) *Monatsh Chem* (in press)
24. Abdel-Wahab BF, Abdel-Aziz HA, Ahmed EM (2008) *Eur J Med Chem* (in press)
25. Abdel-Wahab BF, Abdel-Aziz HA, Ahmed EM (2008) *Arch Pharm* 341:734
26. Vainilavicius P, Smicius R, Jakubkiene V, Tumkevicius S (2001) *Monatsh Chem* 132:825
27. Dawood KM, Farag AF, Abdel-Aziz HA (2005) *Heteroatom Chem* 16:621
28. Reeves DS, White LO (1983) *Principles of methods of assaying antibiotic in pharmaceutical microbiology*, 3rd edn. Blackwell, Oxford, pp 140–162